Clinical applications of palmitoylethanolamide in pain management: protocol for a scoping review

BACKGROUND: Palmitoylethanolamide (PEA) belong to endocannabinoid family, a group of fatty acid amides. PEA has been proven to have analgesic and anti-inflammatory activity and has been used in several controlled studies focused on the management of chronic pain among adult patients with different underlying clinical conditions. METHODS/DESIGN: A literature search will be performed using PubMed, EMBASE, and the Cochrane Central Register of Controlled Trials (CENTRAL). The population will be patients who have chronic pain, the intervention will be the administration of PEA alone or in combination with other drugs for the pain management; the comparison will be the standard therapy in accordance with the current guidelines for the treatment of pain. The Outcomes will be the reduction of pain not restricted to specific scales laying out the pain outcome data described in the included studies. DISCUSSION: This scoping review aims to describe the clinical applications of the PEA in chronic pain management and its outcome. SCOPING REVIEW REGISTRATION: Open Science Framework https://osf.io/74tmx/.